Doxorubicin + Carmustine + Cyclophosphamide

The combination of adriamycin (doxorubicin), carmustine (BCNU), and cyclophosphamide is a polychemotherapy regimen that has been used in the treatment of various cancers, particularly advanced ovarian cancer[1][6]. This combination therapy works by damaging the DNA inside cancer cells, preventing them from dividing and ultimately causing them to die[3]. ## Mechanism of Action Each component of this combination has a specific role: - **Adriamycin (doxorubicin)**: An anthracycline that damages DNA and stops cancer cells from continuing to grow. It works at any point in the cell cycle[3]. - **Carmustine (BCNU)**: A nitrosourea alkylating agent that cross-links DNA strands, preventing cell division. - **Cyclophosphamide**: An alkylating agent that stops cancer cells from reproducing. It works when cells are in their resting phase (not dividing)[3]. ## Clinical Use and Efficacy This combination therapy has shown effectiveness in treating advanced ovarian cancer, with studies reporting complete remission in 33.3% of subjects and partial remission in 37.5% of patients[1][6]. The treatment is administered intravenously, with specific dosing schedules. ## Side Effects Common side effects of this combination include: - Nausea and vomiting - Alopecia (hair loss) - Myelosuppression (though reported as "acceptable" in studies)[1] Notably, no heart damage was observed in the studies examining this combination for ovarian cancer treatment[1]. ## Related Combinations While the specific combination of adriamycin + carmustine + cyclophosphamide is documented for ovarian cancer, similar combinations have been used for other cancers: - AC (adriamycin + cyclophosphamide) is commonly used for breast cancer treatment[2][3][7] - Combinations including these agents along with others like etoposide have been used for aggressive non-Hodgkin lymphoma[4] - Various combinations of adriamycin with other agents have been studied for soft tissue sarcomas[5] This polychemotherapy combination represents one of several multi-agent approaches developed to improve cancer treatment outcomes through synergistic drug effects.

Other names

Adriamycin + Carmustine + Cyclophosphamide